Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIMM 2
NCT05173714Phase 2Recruiting
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in chronic kidney disease (CKD) and obesity (3 arms). Primary endpoint: Average Change in Sedentary Duration at 12 months. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on NCT05173714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173714.